Related Experiment Video

Updated: Sep 29, 2025

Orthotopic Transplantation of Breast Tumors as Preclinical Models for Breast Cancer
07:45

Orthotopic Transplantation of Breast Tumors as Preclinical Models for Breast Cancer

Published on: May 18, 2020

6.3K

Breast Tumour Kinase (Brk/PTK6) Contributes to Breast Tumour Xenograft Growth and Modulates Chemotherapeutic

Rajpal S Burmi1, Gary M Box2, Umar Wazir3

  • 1Centre for Genome Engineering and Maintenance, Institute for Health Medicine and Environments, Brunel University London, Uxbridge UB8 3PH, UK.

Genes
|March 25, 2022
PubMed

Insights

Breast tumour kinase (Brk/PTK6) overexpression correlates with poor breast cancer outcomes. While kinase-inactive Brk promotes tumor growth, inhibiting Brk enhances chemotherapy sensitivity in triple-negative breast cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Breast tumour kinase (Brk/PTK6) is frequently overexpressed in breast cancers, correlating with adverse patient prognoses.
  • Its precise role in tumorigenesis and therapeutic potential, particularly its kinase activity, remains incompletely understood.
  • Triple-negative breast cancer (TNBC) presents a significant clinical challenge, necessitating novel therapeutic strategies.

Purpose of the Study:

  • To investigate the function of the Brk/PTK6 kinase domain in promoting tumor growth.
  • To evaluate the potential of Brk/PTK6 inhibition in sensitizing triple-negative breast cancer cells to chemotherapy.
  • To explore the prognostic significance of Brk/PTK6 isoforms in breast cancer patient outcomes.

Main Methods:

  • Utilized triple-negative human xenograft models to assess the impact of wild-type and kinase-inactive Brk/PTK6 on tumor growth.
  • Investigated the effect of Brk/PTK6 activity suppression on the sensitivity of triple-negative breast cancer cell lines to doxorubicin and paclitaxel.
  • Analyzed the correlation between the expression of the alternatively spliced isoform, ALT-PTK6, and patient outcomes.

Main Results:

  • Both kinase-inactive and wild-type Brk/PTK6 were found to promote xenograft growth in triple-negative models.
  • Suppression of Brk/PTK6 kinase activity significantly increased the sensitivity of cancer cells to doxorubicin and paclitaxel in vitro.
  • High expression of the ALT-PTK6 isoform was associated with improved patient outcomes.
  • The study identified a role for kinase-inactive Brk/PTK6 in xenograft growth, suggesting isolated kinase inhibition may not suffice for halting tumor progression in vivo.

Conclusions:

  • Kinase inhibition of Brk/PTK6 may not be sufficient as a standalone therapy for breast cancer due to the contribution of kinase-inactive forms to tumor growth.
  • Brk/PTK6 kinase activity is crucial for breast cancer cell response to chemotherapy, indicating potential for combinatorial therapeutic approaches.
  • The ratio of ALT-PTK6 to Brk/PTK6 expression holds significant prognostic value for predicting patient outcomes in breast cancer.
Keywords:
ALT-PTK6Brk/PTK6breast cancerchemotherapykinaseprognosis

More Related Videos

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.1K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.4K

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
4.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.9K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.0K